The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country comparison of the results of the CUA and BIA and detail...
Saved in:
| Main Authors: | Jesper Jørgensen, Spiros Servos, Panos Kefalas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2018.1500419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
by: Jesper Jørgensen, et al.
Published: (2019-01-01) -
Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
by: Jesper Jørgensen, et al.
Published: (2017-01-01) -
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
by: Jesper Jørgensen, et al.
Published: (2019-01-01) -
PHARMACOECONOMIC ANALYSIS OF THE IMPACT ON THE BUDGET COSTS OF ADDING DEXMEDETOMIDINE (DEXDOR) INTO THE LIST OF VITAL AND ESSENTIAL DRUGS
by: S. L. Plavinskiy, et al.
Published: (2017-11-01) -
Affordability of oncology drugs: accuracy of budget impact estimations
by: Joost W. Geenen, et al.
Published: (2020-01-01)